DGIdb - TROGLITAZONE Drug Record

TROGLITAZONE chembl:CHEMBL408

Alternate Names:

TROGLITAZONE
ROMOZIN
GR92132X
PRELAY
REZULIN
CS-045
GR-92132X
CI-991
REZULIN®
REZULIN (TN)
ROMGLIZONE
5-(4-(6-HYDROXY-2,5,7,8-TETRAMETHYLCHROMAN-2-YLMETHOXY)BENZYL)THIAZOLIDINE-2,4-DIONE
(+-)-ALL-RAC-5-(P-((6-HYDROXY-2,5,7,8-TETRAMETHYL-2-CHROMANYL)METHOXY)BENZYL)-2,4-THIAZOLIDINEDIONE
rxcui:72610
chembl:CHEMBL408
drugbank:00197
pubchem.compound:5591
chemidplus:97322-87-7

Drug Info:

Drug Categories	ugt1a6 inhibitors
Drug Categories	thiazolidinediones
Drug Categories	cytochrome p-450 cyp2c19 inhibitors
Drug Groups	approved
Drug Groups	investigational
Drug Categories	blood glucose lowering agents
Drug Categories	chromans
Drug Categories	cytochrome p-450 cyp2b6 inducers (strength unknown)
Drug Categories	cytochrome p-450 cyp2c19 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp2c8 inhibitors (moderate)
Drug Categories	cytochrome p-450 cyp2c9 inhibitors (moderate)
Drug Categories	cytochrome p-450 cyp3a4 inducers
Drug Categories	cytochrome p-450 cyp3a4 inducers (strength unknown)
Drug Categories	cytochrome p-450 cyp3a5 inhibitors
Drug Categories	cytochrome p-450 cyp3a5 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 cyp3a7 inhibitors
Drug Categories	cytochrome p-450 cyp3a7 inhibitors (strength unknown)
Drug Categories	cytochrome p-450 enzyme inhibitors
Drug Categories	cytochrome p-450 substrates
Drug Categories	heterocyclic compounds, fused-ring
Drug Categories	oatp1b1/slco1b1 inhibitors
Drug Categories	ugt1a1 substrates
Drug Categories	ugt1a3 substrates
Drug Categories	ugt1a4 substrates
Drug Categories	ugt1a6 substrate
Drug Categories	ugt1a9 substrates
Drug Categories	ugt2b7 substrates

(4 More Sources)

Publications:

Cominacini et al., 1999, The expression of adhesion molecules on endothelial cells is inhibited by troglitazone through its antioxidant activity., Cell Adhes. Commun.
Hoang MH et al., 2012, Ethyl 2,4,6-trihydroxybenzoate is an agonistic ligand for liver X receptor that induces cholesterol efflux from macrophages without affecting lipid accumulation in HepG2 cells., Bioorg Med Chem Lett
Kitamura et al., 1999, Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells., Jpn. J. Cancer Res.
Satoh et al., 1999, Prostaglandin J2 and its metabolites promote neurite outgrowth induced by nerve growth factor in PC12 cells., Biochem. Biophys. Res. Commun.
Hong SS et al., 2012, Acetylenic acid analogues from the edible mushroom Chanterelle (Cantharellus cibarius) and their effects on the gene expression of peroxisome proliferator-activated receptor-gamma target genes., Bioorg Med Chem Lett
Hiep NT et al., 2012, Polyhydroxylated macrolides from Seimatosporium discosioides and their effects on the activation of peroxisome proliferator-activated receptor gamma., J Nat Prod
Petrova et al., 1999, Cyclopentenone prostaglandins suppress activation of microglia: down-regulation of inducible nitric-oxide synthase by 15-deoxy-Delta12,14-prostaglandin J2., Proc. Natl. Acad. Sci. U.S.A.
Baek et al., 2003, Troglitazone, a peroxisome proliferator-activated receptor gamma (PPAR gamma ) ligand, selectively induces the early growth response-1 gene independently of PPAR gamma. A novel mechanism for its anti-tumorigenic activity., J. Biol. Chem.
Demetri et al., 1999, Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma., Proc. Natl. Acad. Sci. U.S.A.
Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
Camp et al., 1999, PPARgamma activators down-regulate the expression of PPARgamma in 3T3-L1 adipocytes., FEBS Lett.
MacDonald ML et al., 2006, Identifying off-target effects and hidden phenotypes of drugs in human cells., Nat Chem Biol
Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
Furuta et al., 2002, Troglitazone improves GLUT4 expression in adipose tissue in an animal model of obese type 2 diabetes mellitus., Diabetes Res. Clin. Pract.
Sharma et al., 2004, Peroxisome proliferator-activated receptor gamma activation modulates cyclin D1 transcription via beta-catenin-independent and cAMP-response element-binding protein-dependent pathways in mouse hepatocytes., J. Biol. Chem.
Watanabe et al., 2003, A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus., Clin. Pharmacol. Ther.
Nozawa et al., 2004, Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity., Drug Metab. Dispos.
Kruszynska et al., 2000, Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects., Diabetes
Sobel, 1999, Insulin resistance and thrombosis: a cardiologist's view., Am. J. Cardiol.
Nordt et al., 2000, Differential regulation by troglitazone of plasminogen activator inhibitor type 1 in human hepatic and vascular cells., J. Clin. Endocrinol. Metab.
Kato et al., 2000, Improvement by the insulin-sensitizing agent, troglitazone, of abnormal fibrinolysis in type 2 diabetes mellitus., Metab. Clin. Exp.
Gottschling-Zeller et al., 2000, Troglitazone reduces plasminogen activator inhibitor-1 expression and secretion in cultured human adipocytes., Diabetologia
Wang et al., 2010, Troglitazone is an estrogen-related receptor alpha and gamma inverse agonist., Biochem. Pharmacol.
Lewin et al., 2002, Rat liver acyl-CoA synthetase 4 is a peripheral-membrane protein located in two distinct subcellular organelles, peroxisomes, and mitochondrial-associated membrane., Arch. Biochem. Biophys.
Lewin et al., 2001, Acyl-CoA synthetase isoforms 1, 4, and 5 are present in different subcellular membranes in rat liver and can be inhibited independently., J. Biol. Chem.
Kim et al., 2001, Expression and characterization of recombinant rat Acyl-CoA synthetases 1, 4, and 5. Selective inhibition by triacsin C and thiazolidinediones., J. Biol. Chem.
Yoshioka et al., 2001, Troglitazone enhances glucose uptake induced by alpha-adrenoceptor stimulation via phosphatidylinositol 3-kinase in rat heart., Clin. Exp. Pharmacol. Physiol.
Ohta et al., 2001, Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells., J. Clin. Endocrinol. Metab.
Yamanaka et al., 2007, Comparison of the antidiabetic effects of brain-derived neurotrophic factor and thiazolidinediones in obese diabetic mice., Diabetes Obes Metab
Lappas et al., 2002, Regulation of proinflammatory cytokines in human gestational tissues by peroxisome proliferator-activated receptor-gamma: effect of 15-deoxy-Delta(12,14)-PGJ(2) and troglitazone., J. Clin. Endocrinol. Metab.
Leung et al., 2005, Effect of thiazolidinediones on equilibrative nucleoside transporter-1 in human aortic smooth muscle cells., Biochem. Pharmacol.
Watanabe et al., 2002, Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10., Drug Metab. Dispos.
Yin et al., 2004, Signaling pathways involved in induction of GADD45 gene expression and apoptosis by troglitazone in human MCF-7 breast carcinoma cells., Oncogene
Murata et al., 2000, Stimulation by eicosapentaenoic acids of leptin mRNA expression and its secretion in mouse 3T3-L1 adipocytes in vitro., Biochem. Biophys. Res. Commun.
Piva et al., 2005, 15-Deoxy-delta 12,14-prostaglandin J2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-kappa B activity and down-regulation of antiapoptotic proteins., Blood
Cefalu et al., 2004, Effects of insulin sensitizers on plaque vulnerability associated with elevated lipid content in atheroma in ApoE-knockout mice., Acta Diabetol
Patel et al., 2005, Differential modulation of COX-2 expression in A549 airway epithelial cells by structurally distinct PPAR(gamma) agonists: evidence for disparate functional effects which are independent of NF-(kappa)B and PPAR(gamma)., Cell. Signal.
Inoue et al., 2002, Fibrate and statin synergistically increase the transcriptional activities of PPARalpha/RXRalpha and decrease the transactivation of NFkappaB., Biochem. Biophys. Res. Commun.
Boerma JS et al., 2011, Application of CYP102A1M11H as a tool for the generation of protein adducts of reactive drug metabolites., Chem Res Toxicol

TROGLITAZONE ACSL4

Interaction Score: 2.23

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
12147264 11319232 11319222

Sources:
DrugBank
TROGLITAZONE GADD45A

Interaction Score: 0.67

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15064713

Sources:
NCI
TROGLITAZONE VCAM1

Interaction Score: 0.42

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10626906

Sources:
NCI
TROGLITAZONE SERPINE1

Interaction Score: 0.37

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

PMIDs:
10871202 10418858 10770198 10831180 10768100

Sources:
DrugBank
TROGLITAZONE UGT1A10

Interaction Score: 0.33

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12433820

Sources:
NCI
TROGLITAZONE GSTT1

Interaction Score: 0.3

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12732844

Sources:
PharmGKB
TROGLITAZONE ESRRG

Interaction Score: 0.26

Interaction Types & Directionality:

inverse agonist (inhibitory)

Interaction Info:

PMIDs:
20298676

Sources:
DrugBank
TROGLITAZONE ESRRA

Interaction Score: 0.26

Interaction Types & Directionality:

inverse agonist (inhibitory)

Interaction Info:

PMIDs:
20298676

Sources:
DrugBank
TROGLITAZONE LEP

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10753628

Sources:
NCI
TROGLITAZONE SLC29A1

Interaction Score: 0.21

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
15963471

Sources:
DrugBank
TROGLITAZONE APOE

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15057551

Sources:
NCI
TROGLITAZONE CCND1

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14764597

Sources:
NCI
TROGLITAZONE TRPM3

Interaction Score: 0.15

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Specific Action of the Ligand None

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
GuideToPharmacology
TROGLITAZONE PPARG

Interaction Score: 0.15

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Specific Action of the Ligand Full agonist

Endogenous Drug? False

Direct Interaction? True

PMIDs:
22579484 10076568 10222233 22342624 22424300 10200320 12475986 10097144 11752352 10214942 16680159

Sources:
DTC TTD DrugBank GuideToPharmacology ChemblInteractions
TROGLITAZONE XIAP

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15498850

Sources:
NCI
TROGLITAZONE GSTM1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12732844

Sources:
NCI
TROGLITAZONE SLCO1B1

Interaction Score: 0.09

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14977862

Sources:
NCI PharmGKB
TROGLITAZONE MYC

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11344222

Sources:
NCI
TROGLITAZONE SLC2A4

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11947963

Sources:
NCI
TROGLITAZONE GSTP1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21639118

Sources:
DrugBank
TROGLITAZONE CXCL8

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
12364456

Sources:
NCI
TROGLITAZONE PIK3CB

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11553036

Sources:
NCI
TROGLITAZONE BDNF

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
17924870

Sources:
NCI
TROGLITAZONE PPARA

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11779144

Sources:
DrugBank
TROGLITAZONE PIK3CG

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15993751

Sources:
NCI
TROGLITAZONE ALOX15B

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC
TROGLITAZONE PPARD

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11779144

Sources:
DrugBank
TROGLITAZONE NR1I2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
TROGLITAZONE CYP2C9

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
TROGLITAZONE CYP2C19

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
TROGLITAZONE CYP1A2

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
TROGLITAZONE CYP2D6

Interaction Score: 0.01

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
TROGLITAZONE CYP3A4

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22931300

Sources:
DTC
TROGLITAZONE NFE2L2

Interaction Score: 0.0

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
DTC

DrugBank: DB00197

Version: 5.1.7

Alternate Names:

TROGLITAZONE DrugBank Drug Name

97322-87-7 CAS Number

Noscal Drug Brand

Drug Info:

Drug Type small molecule

Drug Groups approved

Drug Groups investigational

Publications:

Wang et al., 2010, Troglitazone is an estrogen-related receptor alpha and gamma inverse agonist., Biochem. Pharmacol.

Kruszynska et al., 2000, Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects., Diabetes

Sobel, 1999, Insulin resistance and thrombosis: a cardiologist's view., Am. J. Cardiol.

NCI: TROGLITAZONE

Version: 14-September-2017

Alternate Names:

C1522 NCI drug code

Drug Info:

Publications:

Cominacini et al., 1999, The expression of adhesion molecules on endothelial cells is inhibited by troglitazone through its antioxidant activity., Cell Adhes. Commun.

Furuta et al., 2002, Troglitazone improves GLUT4 expression in adipose tissue in an animal model of obese type 2 diabetes mellitus., Diabetes Res. Clin. Pract.

Piva et al., 2005, 15-Deoxy-delta 12,14-prostaglandin J2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-kappa B activity and down-regulation of antiapoptotic proteins., Blood

DTC: TROGLITAZONE

Version: 02-September-2020

Alternate Names:

CHEMBL408 ChEMBL Drug ID

Drug Info:

Publications:

Hoang MH et al., 2012, Ethyl 2,4,6-trihydroxybenzoate is an agonistic ligand for liver X receptor that induces cholesterol efflux from macrophages without affecting lipid accumulation in HepG2 cells., Bioorg Med Chem Lett

Hong SS et al., 2012, Acetylenic acid analogues from the edible mushroom Chanterelle (Cantharellus cibarius) and their effects on the gene expression of peroxisome proliferator-activated receptor-gamma target genes., Bioorg Med Chem Lett

Hiep NT et al., 2012, Polyhydroxylated macrolides from Seimatosporium discosioides and their effects on the activation of peroxisome proliferator-activated receptor gamma., J Nat Prod

PharmGKB: troglitazone

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Watanabe et al., 2003, A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus., Clin. Pharmacol. Ther.

Nozawa et al., 2004, Involvement of organic anion transporting polypeptides in the transport of troglitazone sulfate: implications for understanding troglitazone hepatotoxicity., Drug Metab. Dispos.

TTD: Troglitazone
- Version: 2020.06.01
Alternate Names:

D06XZW TTD Drug ID

Drug Info:

Publications:
GuideToPharmacology: 135651283
- Version: 29-September-2020
Alternate Names:

TROGLITAZONE GuideToPharmacology Ligand Name

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL408
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:
ChemblInteractions: CHEMBL408
- Version: chembl_23
Alternate Names:

Drug Info:

Publications:

Specific Action of the Ligand	None
Endogenous Drug?	False
Direct Interaction?	False

Specific Action of the Ligand	Full agonist
Endogenous Drug?	False
Direct Interaction?	True

TROGLITAZONE	DrugBank Drug Name
97322-87-7	CAS Number
Noscal	Drug Brand

Drug Type	small molecule
Drug Groups	approved
Drug Groups	investigational

TROGLITAZONE Drug Record

TROGLITAZONE chembl:CHEMBL408

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 12147264 11319232 11319222

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15064713

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10626906

Sources: NCI

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info:

PMIDs: 10871202 10418858 10770198 10831180 10768100

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12433820

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12732844

Sources: PharmGKB

Interaction Types & Directionality: inverse agonist (inhibitory)

Interaction Info:

PMIDs: 20298676

Sources: DrugBank

Interaction Types & Directionality: inverse agonist (inhibitory)

Interaction Info:

PMIDs: 20298676

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10753628

Sources: NCI

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info:

PMIDs: 15963471

Sources: DrugBank

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15057551

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14764597

Sources: NCI

Interaction Types & Directionality: blocker (inhibitory)

Interaction Info: Specific Action of the Ligand None Endogenous Drug? False Direct Interaction? False

PMIDs: None found

Sources: GuideToPharmacology

Interaction Types & Directionality: agonist (activating)

Interaction Info: Specific Action of the Ligand Full agonist Endogenous Drug? False Direct Interaction? True

PMIDs: 22579484 10076568 10222233 22342624 22424300 10200320 12475986 10097144 11752352 10214942 16680159

Sources: DTC TTD DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 15498850

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 12732844

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 14977862

Sources: NCI PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11344222

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 11947963

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
12147264 11319232 11319222

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
15064713

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
10626906

Sources:
NCI

Interaction Types & Directionality:

antagonist (inhibitory)

PMIDs:
10871202 10418858 10770198 10831180 10768100

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
12433820

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
12732844

Sources:
PharmGKB

Interaction Types & Directionality:

inverse agonist (inhibitory)

PMIDs:
20298676

Sources:
DrugBank

Interaction Types & Directionality:

inverse agonist (inhibitory)

PMIDs:
20298676

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
10753628

Sources:
NCI

Interaction Types & Directionality:

inhibitor (inhibitory)

PMIDs:
15963471

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
15057551

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
14764597

Sources:
NCI

Interaction Types & Directionality:

blocker (inhibitory)

Interaction Info:

Specific Action of the Ligand None

Endogenous Drug? False

Direct Interaction? False

PMIDs:
None found

Sources:
GuideToPharmacology

Interaction Types & Directionality:

agonist (activating)

Interaction Info:

Specific Action of the Ligand Full agonist

Endogenous Drug? False

Direct Interaction? True

PMIDs:
22579484 10076568 10222233 22342624 22424300 10200320 12475986 10097144 11752352 10214942 16680159

Sources:
DTC TTD DrugBank GuideToPharmacology ChemblInteractions

Interaction Types & Directionality:

n/a

PMIDs:
15498850

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
12732844

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
14977862

Sources:
NCI PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
11344222

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
11947963

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
21639118

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
12364456

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
11553036

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
17924870

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
11779144

Sources:
DrugBank

Interaction Types & Directionality:

n/a

PMIDs:
15993751

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
DTC